The FDA has granted Orphan Drug Designation to LMP744, an indenoisoquinoline-based topoisomerase I inhibitor, for treating gliomas, a rare and life-threatening group of brain tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.